With 0.87 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.19 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.83 whereas the lowest price it dropped to was $3.5799. The 52-week range on ELEV shows that it touched its highest point at $5.89 and its lowest point at $0.36 during that stretch. It currently has a 1-year price target of $7.75. Beta for the stock currently stands at 1.52.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ELEV was down-trending over the past week, with a drop of -4.74%, but this was down by -27.74% over a month. Three-month performance surged to 31.16% while six-month performance rose 514.39%. The stock gained 19.47% in the past year, while it has gained 574.12% so far this year. A look at the trailing 12-month EPS for ELEV yields -1.53 with Next year EPS estimates of -0.89. For the next quarter, that number is -0.20. This implies an EPS growth rate of 36.27% for this year and -3.98% for next year.
Float and Shares Shorts:
At present, 42.42 million ELEV shares are outstanding with a float of 37.99 million shares on hand for trading. On 2024-04-15, short shares totaled 4.95 million, which was 1018.0 higher than short shares on 1710460800. In addition to Dr. David Dornan Ph.D. as the firm’s Chief Scientific Officer, Ms. Valerie Malyvanh Jansen M.D., Ph.D. serves as its Chief Medical Officer.
Institutional Ownership:
Through their ownership of 0.86434996 of ELEV’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, ELEV reported revenue of $0.0 and operating income of -$7946000.0. The EBITDA in the recently reported quarter was -$7936000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ELEV since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
